期刊文献+

促甲状腺激素对破骨细胞分化的影响 被引量:3

Effects of thyroid stimulating hormone on osteoclast differentiation
原文传递
导出
摘要 目的探讨促甲状腺激素(TSH)对小鼠单核/巨噬细胞系RAW264.7细胞诱导分化为破骨样细胞过程的影响。方法体外培养小鼠单核/巨噬细胞系RAW264.7细胞,以破骨细胞分化因子(RANKL)诱导分化,同时加用不同浓度TSH处理7 d,抗酒石酸酸性磷酸酶(TRAP)染色鉴定并计数阳性细胞数量,采用Real-time PCR方法检测分化标志蛋白TRAP、基质金属蛋白酶-9(MMP-9)及组织蛋白酶K(Cathepsin K)的基因表达。结果RAW264.7细胞可在RANKL诱导下分化为破骨样细胞,高表达TRAP、M M P-9和Cathepsin K基因,TSH可剂量依赖性抑制细胞分化并下调上述基因的表达。结论 TSH可抑制破骨细胞的分化,对于维持骨量可能具有重要作用。 Objective To study the effects of thyroid stimulating hormone (TSH) on the differentiation of RAW264.7 cells into osteoclast like cells. Methods RAW264.7 cells were induced to differentiate into osteoclasts by addition of ligand of receptor activator of NF-KB (RANKL), and treated with different doses of TSH for 7 days. Tartrate resistant acid phosphatase (TRAP) staining was used to identify and count osteoclasts. The mRNA expression of osteoclastic phenotypes and functioning genes including TRAP, matrix metalloproteinase-9 (MMP-9) and Cathepsin K in different groups were detected by Real-time PCR. Results RAW264.7 cells could be induced to differentiate into mature osteo- clasts and express high levels of TRAP, MMP-9 and Cathepsin K by RANKL. TSH dose-dependently inhibited the cell differentiation and down-regulated the expression of the genes above including TRAP, MMP-9 and Cathepsin K. Con- dusion TSH negatively regulates osteoclast differentiation, which may contribute to the maintenance of bone mass.
出处 《山东大学学报(医学版)》 CAS 北大核心 2013年第4期6-10,17,共6页 Journal of Shandong University:Health Sciences
基金 山东省优秀中青年科学家科研奖励基金(2007BS03004)
关键词 促甲状腺激素 RAW264 7细胞 破骨细胞 分化 Thyroid stimulating hormone RAW264.7 cells Osteoclast Differentiation
  • 相关文献

参考文献23

  • 1HolloweU J G, Staehling N W, Flanders W D, et al. Ser- um TSH, T (4), and thyroid antibodies in the United States population ( 1988 to 1994 ) : National Health and Nutrition Examination Survey ( NHANES III) [ J ]. J Clin Endocrinol Metab, 2002, 87 (2) :489-499.
  • 2Foldes J, Tarjan G, Szathmari M, et al. Bone mineral density in patients with endogenous subclinical hyperthy- roidism: is this thyroid status a risk factor for osteoporo- sis? [J]. Clin Endocrinol (Oxf), 1993, 39(5):521- 527.
  • 3Mudde A H, Houben A J, Nieuwenhuijzen Kruseman A C. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism E J ]. Clin Endo- crinol( Oxf), 1994, 41 (4) :421-424.
  • 4Zaidi M, Davies T F, Zallone A, et al. Thyroid-stimula- ting hormone, thyroid hormones, and bone loss [ J ]. Curr Osteoporos Rep, 2009, 7 (2) :47-52.
  • 5Williams G R. Does serum TSH level have thyroid hor- mone independent effects on bone turnover? [ J ]. Nat Clin Pract Endocrinol Metab, 2009, 5 ( 1 ) : 10-11.
  • 6Lakkakorpi P T, Vaananen H K. Kinetics of the osteo- clast cytoskeleton during the resorption cycle in vitro E J ]- J Bone Miner Res, 1991, 6(8) :817-826.
  • 7Yasuda H, Shima N, Nakagawa N, et al. Osteoclast dif- ferentiation factor is a ligand for osteoprotegerin/oste- oclastogenesis-inhibitory factor and is identical to TRANCE/RANKL E J]. Proc Natl Acad Sci U S A, 1998, 95(7) :3597-3602.
  • 8Okada Y, Naka K, Kawamura K, et al. Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV collagenase = gelatinase B ) in osteoclasts: implica- tions for bone resorption [J ]. Lab Invest, 1995, 72 (3) : 311-322.
  • 9Walker D G. Osteopetrosis cured by temporary parabiosis [J ]. Science, 1973, 180(4088):875.
  • 10Schroder H C, Wang X H, Wiens M, et al. Silicate modulates the cross-talk between osteoblasts (SaOS-2) and osteoclasts ( RAW 264.7 cells) : inhibition of osteo- clast growth and differentiation E J ]. J Cell Biochem, 2012, 113(10) .3197-3206.

二级参考文献8

  • 1Teitelbaum SL. Bone resorption by osteoclasts. Science, 2000,289: 1504-1508.
  • 2Tanaka S, Takahashi N, Udagawa N, et al. Macrophage colony stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest, 1993,91 : 257-263.
  • 3Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocrine Review, 1996, 20: 345-357.
  • 4Vant Hof RJ, Ralston SH. Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity. Bone Miner Res,1997, 12: 1797-1804.
  • 5Battaglino R, Kim J, Vaage B, et al. C-mys is required for osteoclast differentiation. J Bone Miner Res, 2002, 5: 763-773.
  • 6Roodman GD. Advances in bone biology: the osteoclast. Endocrine Reviews, 1996, 17: 308-332.
  • 7Hsu H, Lacey D, Dunstan C, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA, 1999, 96: 3540-3545.
  • 8伍贤平,廖二元,伍汉文.破骨细胞及其调节机制的某些进展[J].中华内分泌代谢杂志,2002,18(2):157-160. 被引量:6

共引文献9

同被引文献37

  • 1Crisanti P, Omri B, Hughes E, et al. The expression of thyrotropin receptor in the brain [ J ]. Endocrinology, 2001, 142(2) :812-822.
  • 2Paschke R, Geenen V. Messenger RNA expression for aTSH receptor variant in the thymus of a two-year-old child IJ]. JMolMed (Bed), 1995, 73(11) :577-580.
  • 3Endo T, Ohta K, Haraguchi K, et al. Cloning and func- tional expression of a thyrotropin receptor cDNA from rat fat cells [J]. J Biol Chem, 1995, 270 ( 18 ) : 10833-10837.
  • 4Mengistu M, Lukes Y G, Nagy E V, et al. TSH receptor gene expression in retroocular fibroblast J]. J Endocrinol Invest, 1994, 17(6):437-441.
  • 5Davies T, Marians R, Latif R. The TSH receptor reveals itself[J]. I Clin Invest, 2002, 110(2) :161-164.
  • 6Zhang W, Tian L M, Han Y, et al. Presence of thyrotro- pin receptor in hepatocytes: not a case of illegitimate tran- scription[J]. J Cell/Viol Med, 2009, 13(11-12) :4636-4642.
  • 7Tian L, Song Y, Xing M, et al. A novel role for thyroid- stimulating hormone: up-regulation of hepatic 3-hydroxy- 3-methyl-glutaryl-coenzyme A reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate-responsive element binding pro- tein pathway[J]. Hepatology, 2010, 52(4):1401-1409.
  • 8Munday M R. Regulation of mammalian acetyl-CoA car- boxylase[J]. Biochem Soc Trans, 2002, 30 ( Pt 6) : 1059-1064.
  • 9Djouder N, Tuerk R D, Suter M, et al. PKA phospho- rylates and inactivates AMPKalpha to promote efficient lipolysis[J]. EMBO J, 2010, 29(2) :469-481.
  • 10Viollet B, Andreelli F. AMP-activated protein kinase and metabolic control[ J]. Handb Exp Pharmacol, 2011 ( 203 ) :303-330.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部